Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M64.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score5.8
Enterprise Value $M60.7EPS (TTM) $-0.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.710-y EBITDA Growth Rate %--Quick Ratio11.7Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio11.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-33.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M56.4ROIC % (ttm)-50.1Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BLRX is held by these investors:



BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BLRX:

    News about BLRX:

    Articles On GuruFocus.com
    Analysts Positive on BioLineRx Ltd. Following Ph2 Testing Expansion for AML May 05 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

    More From Other Websites
    Coverage initiated on BioLineRx by Rodman & Renshaw Feb 13 2017
    BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 Feb 07 2017
    BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda Jan 19 2017
    BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of... Jan 17 2017
    BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco Jan 04 2017
    BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology... Dec 05 2016
    BioLineRx Reports Third Quarter 2016 Financial Results Nov 22 2016
    BioLineRx Reports Third Quarter 2016 Financial Results Nov 22 2016
    BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic... Nov 21 2016
    BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic... Nov 21 2016
    BioLineRx to Report Third Quarter Results on November 22, 2016 Nov 15 2016
    BioLineRx to Report Third Quarter Results on November 22, 2016 Nov 15 2016
    Penny Ante: Ante Up For Bioline RX Ltd (BLRX) Stock Nov 09 2016
    BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data... Nov 03 2016
    BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data... Nov 03 2016
    BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th... Oct 05 2016
    BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement Sep 23 2016
    Why These 5 Stocks Are Winning Today Sep 23 2016
    BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic... Sep 23 2016
    BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic... Sep 23 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)